Please login to the form below

Not currently logged in
Email:
Password:

US bill will force disclosure of doctor payments

A bill introduced in the US Senate will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors

A bill introduced in the US Senate on 6 September 2007 will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors, according to the New York Times.

Companies with at least USD 100m in annual sales would have to disclose gifts or payments exceeding USD 25 in value each quarter, and the information would then be posted on a publicly accessible website.

Companies will have to disclose any payment or benefit made "directly, indirectly, through an agent, subsidiary or other third party", which might include payments by universities and by companies that organise conferences for Key Opinion Leaders (KOLs) with drug or medical device manufacturer funding.

Funding of continuing medical education programmes would also need to be disclosed. No-cost drug samples and financing for clinical trials would not have to be disclosed, according to the bill.

Senate Finance Committee member Chuck Grassley (Republican, Iowa), who is one of the bill's authors, said: "The public has no way to know whether a doctor's been given money that might affect prescribing habits."

Ken Johnson, senior vice-president of the Pharmaceutical Research and Manufacturers of America (PhRMA), countered: "A new law is not necessary when pharmaceutical marketing is already heavily regulated by the FDA."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...